Clinical trials: Patient With Schizophrenia Spectrum Disorder
Schizophrenia
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
- Trial name
- NCT04076371
- Testing
- olanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination
- Volunteers
- 1,640 people
- Sponsor
- Beijing HuiLongGuan Hospital
Schizophrenia, Major Depressive Disorder
Clinical Registry of Patients Under Treatment With Atypical Antipsychotics
Antipsychotic drugs are characterized by blocking dopaminergic D2 receptors. They have been found to be effective and safe for the treatment of schizophrenia, bipolar disorders, depressive episodes associated with bipolar…
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Depressive Disorder, Parkinson's Disease With Hallucinations
- Trial name
- NCT02409823
- Testing
- Atypical Antipsychotics
- Volunteers
- 665 people
- Sponsor
- Pontifical Catholic University of Argentina
Schizophrenia, Schizoaffective Disorder
Estradiol Patch as add-on to Antipsychotics in Patients With Schizophrenia, Schizoaffective or Schizophreniform Disorder
To evaluate the effects of Estradiol patches vs placebo patches as add-on to antipsychotics on psychometric performance in patients with schizophrenia, schizoaffective or schizophreniform disorder
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT03848234
- Testing
- Estradiol
- Where
- Moldova
- Volunteers
- 209 people
- Sponsor
- Tangent Data
Schizophrenia, Negative Symptoms in Schizophrenia
A Study on the Efficacy of Agomelatine Combined With Antipsychotics to Treat Negative Symptoms in Schizophrenia
This study is a prospective, multicenter, controlled, real world study. Patients will be randomly enrolled into the test group and the control group at a ratio of 1:1 during the screening period.
- Trial name
- NCT05646264
- Testing
- Agomelatine
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia
To evaluate the safety and efficacy of Lurasidone initiated with 40mg and 80mg in treatment with acute phase patients with schizophrenia
- Trial name
- NCT05011669
- Testing
- Lurasidone
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Schizophrenia
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia
A study to evaluate the efficacy of 2 fixed-flexible doses of Lu AF11167 on negative symptoms in patients with schizophrenia
- Trial name
- NCT03793712
- Testing
- Lu AF11167 (1-2 mg/day), Lu AF11167 (3-4 mg/day)
- Where
- 53 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 168 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia Disorder
Virtual Reality-Based Smoking Cessation Treatment in Patients With Schizophrenia
Schizophrenia is associated with high rates of cigarette smoking, which contributes to serious physical health problems and reduced life expectancy.
- Trial name
- NCT07618338
- Testing
- Schizophrenia VR Intervention Group, Healthy Control VR Intervention Group
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Dokuz Eylul University
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia and assess whether it changes: how the body processes (uses) glucose (blood sugar) how much…
- Trial name
- NCT05463770
- Testing
- SEP-363856
- Where
- 8 sites in United States
- Volunteers
- 15 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Diagnostic Announcement to Relatives of Patients With Schizophrenia
The diagnostic announcement of a chronic disorder is an essential step in the patient's care. Recommendations specify the importance of including caregivers at the time of the announcement.
- Trial name
- QUALIPROCHES (NCT04562961)
- Testing
- Schizophrenia caregivers qualitative interview
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Psychotic Disorders
Yoga-based Group Intervention (YoGI) for In-patients With Schizophrenia Spectrum Disorders
A rater-blinded randomized controlled trial with a parallel-group design is utilized, comprised of yoga-based group intervention (YoGI) in the experimental condition, and treatment as usual (TAU) in the control condition.
- Trial name
- YING (NCT04730518)
- Testing
- Yoga-based group intervention (YoGI)
- Where
- Germany
- Volunteers
- 77 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia, Schizophreniform Disorders
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- CR+MCTp (NCT06423651)
- Testing
- Cognitive Remediation (REHACOP), Metacognitive Training (MCT)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Universitat Autonoma de Barcelona
Schizophrenia
Atypical Antipsychotic-induced Mitochondrial Dysfunction in Patients With Schizophrenia
Schizophrenia is a serious mental disorder with a global prevalence of 1%. The main cause of this condition is dysfunction in the signaling of neurotransmitters dopamine, serotonin, glutamate and Gamma-aminobutyric acid…
- Trial name
- NCT06236451
- Testing
- Aripiprazole, Risperidone
- Where
- India
- Volunteers
- 60 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Efficacy of Lu 31-130 in Patients With Schizophrenia
The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.
- Trial name
- NCT00770744
- Testing
- Zicronapine, Olanzapine
- Where
- 21 sites in Czechia, France and 6 more
- Volunteers
- 93 people
- Sponsor
- H. Lundbeck A/S
Mania, Schizophrenia
Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect
With this observational study we want to examine if the intensity of agitation, the intensity of psychotic symptoms and the presence of sleeping disorder predict the success of the treatment with a atypical antipsychotic after 12…
- Trial name
- UPTAQE (NCT00534222)
- Where
- 6 sites in Netherlands
- Volunteers
- 387 people
- Sponsor
- AstraZeneca
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
Niacin Skin Flush Response in Patients With Schizophrenia
Patients with schizophrenia have abnormal skin flush response to niacin, but the niacin skin test accuracy is not well studied in these patients.
- Trial name
- NCT02458924
- Testing
- Niacin skin test
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Isfahan University of Medical Sciences
Schizophrenia
A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation
The purpose of this study is to estimate the proportion of participants fulfilling criteria for symptomatic remission following a transition to 12 months treatment with flexible-dose paliperidone palmitate 3 month formulation…
- Trial name
- NCT02713282
- Testing
- Paliperidone palmitate 3 month formulation (PP3M)
- Where
- 46 sites in Croatia, Denmark and 13 more
- Volunteers
- 306 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.